MAXIMUM STANDARDIZED UPTAKE VALUE FROM STAGING FDG-PET/CT DOES NOT PREDICT TREATMENT OUTCOME FOR EARLY-STAGE NON SMALL-CELL LUNG CANCER TREATED WITH STEREOTACTIC BODY RADIOTHERAPY
MAXIMUM STANDARDIZED UPTAKE VALUE FROM STAGING FDG-PET/CT DOES NOT PREDICT TREATMENT OUTCOME FOR EARLY-STAGE NON SMALL-CELL LUNG CANCER TREATED WITH STEREOTACTIC BODY RADIOTHERAPY
复制标题
DOI：
10.1016/j.ijrobp.2009.09.081
复制
发表时间：
2010-11-15
影响因子：
7
通讯作者：
Videtic, Gregory M. M.
中科院分区：
文献类型：
--
作者：
Burdick, Michael J.;Stephans, Kevin L.;Videtic, Gregory M. M.
目的：进行回顾性分析，以确定2-脱氧-2- [（18）F]氟-D-葡萄糖（FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）研究分期的最大标准化摄取值（SUV（max））是否与立体定向体部放疗（SBRT）治疗的早期非小细胞肺癌（NSCLC）的结局相关。2003年10月17日至2007年8月17日期间，72名医学上无法手术的患者接受了SBRT治疗T1- 2N 0 M0 NSCLC。SBRT采用腹部压迫和图像引导SBRT，分3次给予60戈伊，分5次给予50戈伊，或分10次给予50戈伊。考克斯比例风险回归分析，以确定是否PET SUV（最大值）和其他变量的影响结果：纵隔失败（MF），远处转移（DM），和总生存期（OS）。49例患者患有T1 N 0疾病，23例患有T2 N 0疾病。中位SUV（max）为6.55（范围：1.5-21）。中位随访时间为16.9个月（范围：0.1-37.9个月）。有3例局部失败，8例MF，19例DM和30例死亡。2年局部控制率、ME、DM和OS率分别为94.0%、10.4%、30.1%和61.3%。在单变量分析中，PET/CT SUV（max），定义为连续或二分变量，不能预测MF、DM或OS。在多变量分析中，总生存率的唯一预测因素是T1分期（风险比= 0.331 [95%置信区间，0.156-0.701]，p = 0.0039）和吸烟包-年史结论：在接受SBRT治疗的早期NSCLC患者中，治疗前PET SUV（max）不能预测MF、DM或OS。(C)2010年爱思唯尔公司
Purpose: To perform a retrospective review to determine whether maximum standardized uptake values (SUV(max)) from staging 2-deoxy-2- [(18)F] fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) studies are associated with outcomes for early-stage non small-cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT).Methods and Materials: Seventy-two medically inoperable patients were treated between October 17, 2003 and August 17, 2007 with SBRT for T1-2N0M0 NSCLC. SBRT was administered as 60 Gy in 3 fractions, 50 Gy in 5 fractions, or 50 Gy in 10 fractions using abdominal compression and image-guided SBRT. Cox proportional hazards regression was performed to determine whether PET SUV(max) and other variables influenced outcomes: mediastinal failure (MF), distant metastases (DM), and overall survival (OS).Results: Biopsy was feasible in 49 patients (68.1%). Forty-nine patients had T1N0 disease, and 23 had T2N0 disease. Median SUV(max) was 6.55 (range, 1.5-21). Median follow-up was 16.9 months (range, 0.1-37.9 months). There were 3 local failures, 8 MF, 19 DM, and 30 deaths. Two-year local control, ME, DM, and OS rates were 94.0%, 10.4%, 30.1%, and 61.3%, respectively. In univariate analysis, PET/CT SUV(max), defined either as a continuous or dichotomous variable, did not predict for MF, DM, or OS. On multivariable analysis, the only predictors for overall survival were T1 stage (hazard ratio = 0.331 [95% confidence interval, 0.156-0.701],p = 0.0039) and smoking pack-year history (hazard ratio = 1.015 [95% confidence interval, 1.004-1.0261], p = 0.0084).Conclusions: Pretreatment PET SUV(max) did not predict for MF, DM, or OS in patients treated with SBRT for early-stage NSCLC. (C) 2010 Elsevier Inc.